Full Press Release Details
North American Travelan sales up 185% Global sales up 216%
Melbourne, Australia, April 27,
2022: Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral
immunotherapeutics for the treatment of gut mediated diseases, today announced the sales results of its commercially available and over-the-counter
gastrointestinal and digestive health immune supplement Travelan for the third quarter of the fiscal year 2022, ending
North American Travelan sales
were up by 185% and worldwide gross sales grew by 216% YoY in the third quarter of FY22, reaching AU $193K compared to AU $61K in Q3 FY21.
YTD March 31 FY22 worldwide Travelan sales reached AU $392K marking a healthy 340% increase on the same time last year.
In Australia, Travelan sales
increased to AU $24K in Q3 FY22, representing an increase over Q3 FY21 (AU $2K). Coming out of the pandemic and with international travel
on the increase we are starting to see positive signs of sales growth in Q4.
In the US, Travelan sales
were AU $153K for Q3 FY22 (and AU $293K for YTD March 31 FY22) compared with nil for the corresponding periods in FY21. This growth was
attributable to increasing sales in both Passport Health Travel Clinics and on the Amazon e- commerce channel. While not at pre-pandemic
peak, the sales numbers in the US are starting to considerably pick up again.
In mid to late March 2020, the
COVID-19 pandemic resulted in international travel restrictions being enacted in all markets in which Travelan is sold.
This has had significant impact on Travelan sales over the last two years. Positive signs of sales growth are starting
to be demonstrated again, especially in the US, for the first time since the pandemic began. It is encouraging to see positive sales growth
again which is correlating well with the recommencement of international travel. We anticipate sales will continue to improve in Q4 and
during the next fiscal year.
Jerry Kanellos, Ph.D.
Chief Executive Officer
Ph: +61 (0)3 9824 5254
Travelan is an orally administered
passive immunotherapy that prophylactically reduces the likelihood of contracting travelers' diarrhea, a digestive tract disorder
that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan is a highly purified tabletized preparation
of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization
and the pathology associated with travelers' diarrhea. In Australia, Travelan is a listed medicine on the Australian Register
for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers' Diarrhea, reduce the risk of minor gastro-intestinal
disorders and is antimicrobial. In Canada, Travelan is a licensed natural health product (NPN 80046016) and is indicated to reduce
the risk of Travelers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract protection.
About Travelers' diarrhea
Travelers' diarrhea is a
gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella
spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused
with travelers' diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is
an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies
for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one
commercial asset generating revenue. In Australia, Travelan is a listed medicine on the Australian Register of Therapeutic
Goods (AUST L 106709) and is indicated to reduce the risk of Travellers' Diarrhea, reduce the risk of minor gastro-intestinal
disorders and is antimicrobial. In Canada, Travelan is a licenced natural health product (NPN 80046016) and is indicated to
reduce the risk of Travellers' Diarrhea. In the U.S., Travelan is sold as a dietary supplement for digestive tract
protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA).
For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock
value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth
strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the
results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties
relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.